# Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

> **NCT02949128** · PHASE3 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 58 (actual)

## Conditions studied

- Atypical Hemolytic Uremic Syndrome (aHUS)

## Interventions

- **BIOLOGICAL:** Ravulizumab

## Key facts

- **NCT ID:** NCT02949128
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-11
- **Primary completion:** 2023-01-24
- **Final completion:** 2023-01-24
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02949128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02949128, "Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02949128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*